Inflammation and intracellular exposure of dolutegravir, darunavir, tenofovir and emtricitabine in people living with HIV-Reference-Cited by-同舟云学术

Inflammation and intracellular exposure of dolutegravir, darunavir, tenofovir and emtricitabine in people living with HIV

Published:2022-10-11 Issue:3 Volume:89 Page:1020-1026
ISSN:0306-5251
Container-title:British Journal of Clinical Pharmacology
language:en
Short-container-title:Brit J Clinical Pharma

Author:

Ferrara Micol¹^ORCID,Cusato Jessica²,Salvador Elena¹,Trentalange Alice¹,Alcantarini Chiara¹,Trunfio Mattia¹,Cannizzo Elvira Stefania³,Bono Valeria³,Nozza Silvia⁴,De Nicolò Amedeo²,Ianniello Alice²,De Vivo Elisa²,D'Avolio Antonio²^ORCID,Di Perri Giovanni¹,Bonora Stefano¹,Marchetti Giulia³,Calcagno Andrea¹^ORCID

Affiliation:

1. Unit of Infectious Diseases, Department of Medical Sciences University of Turin Turin Italy

2. Laboratory of Clinical Pharmacology and Pharmacogenetics, Department of Medical Sciences University of Turin Turin Italy

3. Department of Health Sciences, Clinic of Infectious Diseases, ASST, Santi Paolo e Carlo University of Milan Milan Italy

4. Department of Infectious Diseases San Raffaele Scientific Institute Milan Italy

Funder

Ministero della Salute

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bcp.15538

Reference35 articles.

1. Closing the Gap: Increases in Life Expectancy among Treated HIV-Positive Individuals in the United States and Canada

2. All-cause mortality in treated HIV-infected adults with CD4 >=500/mm3 compared with the general population: evidence from a large European observational cohort collaboration

3. Inflammatory Markers Associated With Subclinical Coronary Artery Disease: The Multicenter AIDS Cohort Study

4. Monocytes from HIV-infected individuals show impaired cholesterol efflux and increased foam cell formation after transendothelial migration

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Investigational drugs for HIV: trends, opportunities and key players;Expert Opinion on Investigational Drugs;2023-02-01